Lipidprofil és paraoxonáz aktivitás vizsgálata szisztémás lupus erythematosusban

Translated title of the contribution: Analysis of paraoxonase activity and lipid profile in lupus patients

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Immune-inflammatory processes play important role in the pathogenesis of atherosclerosis. Therefore, increasing attention is focused on rheumatic diseases with chronic inflammation, such as systemic lupus erythematosus. Besides direct influences, inflammation may modify the development of atherosclerosis by other mechanisms. Aims: To examine paraaoxonase activity and lipid profile in lupus patients. Methods: Authors entered 37 definitive lupus patients and 30 age- and sex-matched normal controls into the present study. Patients' age was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, disease activity index 2.8 ± 3.4. Lipid parameters (total cholesterol, LDL-C, HDL-C, Apo-Al and ApoB) were determined by an autoanalyser, paraoxonase and arylesterase activities were measured spectrophotometrically. Phenotypic distribution of the enzyme was determined by dual substrate method. Anti-oxLDL was measured by ELISA method, CRP by automatised Immunoassay. Statistical analysis was performed by SPSS program. Results: Despite of long disease duration and low inflammatory activity authors found significantly (p <0.001) decreased paraoxonase activity (121.9 ± 65.9 U/mL) (p <0.001) in lupus as compared to control (188.1 ± 78.9 U/mL), which correlated with the presence of atherothrombotic complications (p = 0.009). High activity BB phenotype did not occur in lupus. Lipid parameters and arylesterase activity were within normal range in both groups. No significant correlation was found between paraoxonase activity and disease activity index, dose of corticosteroid therapy, CRP and anti-oxLDL level. Arylesterase activity did not differ in lupus and control groups. Conclusions: Present results suggest that other mechanisms, e.g. antibodies, genetic factors, alteration in the distribution of HDL-subfractions or ensyme abnormalities in HDL remodelling may stand at the background of reduced paraoxonase activity in lupus.

Original languageHungarian
Pages (from-to)2395-2402
Number of pages8
JournalOrvosi Hetilap
Volume146
Issue number47
Publication statusPublished - 2005

Fingerprint

Aryldialkylphosphatase
Lipids
Atherosclerosis
Apolipoproteins C
Inflammation
Apolipoproteins B
Rheumatic Diseases
Immunoassay
Systemic Lupus Erythematosus
LDL Cholesterol
Adrenal Cortex Hormones
Reference Values
Enzyme-Linked Immunosorbent Assay
Phenotype
Control Groups
Antibodies
Enzymes
arylesterase
oxidized low density lipoprotein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipidprofil és paraoxonáz aktivitás vizsgálata szisztémás lupus erythematosusban. / Kiss, E.; Seres, I.; Kocsis, Zsolt; Tarr, T.; Csípő, I.; Szegedi, G.; Paragh, G.

In: Orvosi Hetilap, Vol. 146, No. 47, 2005, p. 2395-2402.

Research output: Contribution to journalArticle

@article{bdfc6f3f68484461a55146dc08b18885,
title = "Lipidprofil {\'e}s paraoxon{\'a}z aktivit{\'a}s vizsg{\'a}lata sziszt{\'e}m{\'a}s lupus erythematosusban",
abstract = "Introduction: Immune-inflammatory processes play important role in the pathogenesis of atherosclerosis. Therefore, increasing attention is focused on rheumatic diseases with chronic inflammation, such as systemic lupus erythematosus. Besides direct influences, inflammation may modify the development of atherosclerosis by other mechanisms. Aims: To examine paraaoxonase activity and lipid profile in lupus patients. Methods: Authors entered 37 definitive lupus patients and 30 age- and sex-matched normal controls into the present study. Patients' age was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, disease activity index 2.8 ± 3.4. Lipid parameters (total cholesterol, LDL-C, HDL-C, Apo-Al and ApoB) were determined by an autoanalyser, paraoxonase and arylesterase activities were measured spectrophotometrically. Phenotypic distribution of the enzyme was determined by dual substrate method. Anti-oxLDL was measured by ELISA method, CRP by automatised Immunoassay. Statistical analysis was performed by SPSS program. Results: Despite of long disease duration and low inflammatory activity authors found significantly (p <0.001) decreased paraoxonase activity (121.9 ± 65.9 U/mL) (p <0.001) in lupus as compared to control (188.1 ± 78.9 U/mL), which correlated with the presence of atherothrombotic complications (p = 0.009). High activity BB phenotype did not occur in lupus. Lipid parameters and arylesterase activity were within normal range in both groups. No significant correlation was found between paraoxonase activity and disease activity index, dose of corticosteroid therapy, CRP and anti-oxLDL level. Arylesterase activity did not differ in lupus and control groups. Conclusions: Present results suggest that other mechanisms, e.g. antibodies, genetic factors, alteration in the distribution of HDL-subfractions or ensyme abnormalities in HDL remodelling may stand at the background of reduced paraoxonase activity in lupus.",
keywords = "Atherosclerosis, Inflammation, Lipid profile, Paraoxonase, SLE",
author = "E. Kiss and I. Seres and Zsolt Kocsis and T. Tarr and I. Cs{\'i}pő and G. Szegedi and G. Paragh",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2395--2402",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Lipidprofil és paraoxonáz aktivitás vizsgálata szisztémás lupus erythematosusban

AU - Kiss, E.

AU - Seres, I.

AU - Kocsis, Zsolt

AU - Tarr, T.

AU - Csípő, I.

AU - Szegedi, G.

AU - Paragh, G.

PY - 2005

Y1 - 2005

N2 - Introduction: Immune-inflammatory processes play important role in the pathogenesis of atherosclerosis. Therefore, increasing attention is focused on rheumatic diseases with chronic inflammation, such as systemic lupus erythematosus. Besides direct influences, inflammation may modify the development of atherosclerosis by other mechanisms. Aims: To examine paraaoxonase activity and lipid profile in lupus patients. Methods: Authors entered 37 definitive lupus patients and 30 age- and sex-matched normal controls into the present study. Patients' age was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, disease activity index 2.8 ± 3.4. Lipid parameters (total cholesterol, LDL-C, HDL-C, Apo-Al and ApoB) were determined by an autoanalyser, paraoxonase and arylesterase activities were measured spectrophotometrically. Phenotypic distribution of the enzyme was determined by dual substrate method. Anti-oxLDL was measured by ELISA method, CRP by automatised Immunoassay. Statistical analysis was performed by SPSS program. Results: Despite of long disease duration and low inflammatory activity authors found significantly (p <0.001) decreased paraoxonase activity (121.9 ± 65.9 U/mL) (p <0.001) in lupus as compared to control (188.1 ± 78.9 U/mL), which correlated with the presence of atherothrombotic complications (p = 0.009). High activity BB phenotype did not occur in lupus. Lipid parameters and arylesterase activity were within normal range in both groups. No significant correlation was found between paraoxonase activity and disease activity index, dose of corticosteroid therapy, CRP and anti-oxLDL level. Arylesterase activity did not differ in lupus and control groups. Conclusions: Present results suggest that other mechanisms, e.g. antibodies, genetic factors, alteration in the distribution of HDL-subfractions or ensyme abnormalities in HDL remodelling may stand at the background of reduced paraoxonase activity in lupus.

AB - Introduction: Immune-inflammatory processes play important role in the pathogenesis of atherosclerosis. Therefore, increasing attention is focused on rheumatic diseases with chronic inflammation, such as systemic lupus erythematosus. Besides direct influences, inflammation may modify the development of atherosclerosis by other mechanisms. Aims: To examine paraaoxonase activity and lipid profile in lupus patients. Methods: Authors entered 37 definitive lupus patients and 30 age- and sex-matched normal controls into the present study. Patients' age was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, disease activity index 2.8 ± 3.4. Lipid parameters (total cholesterol, LDL-C, HDL-C, Apo-Al and ApoB) were determined by an autoanalyser, paraoxonase and arylesterase activities were measured spectrophotometrically. Phenotypic distribution of the enzyme was determined by dual substrate method. Anti-oxLDL was measured by ELISA method, CRP by automatised Immunoassay. Statistical analysis was performed by SPSS program. Results: Despite of long disease duration and low inflammatory activity authors found significantly (p <0.001) decreased paraoxonase activity (121.9 ± 65.9 U/mL) (p <0.001) in lupus as compared to control (188.1 ± 78.9 U/mL), which correlated with the presence of atherothrombotic complications (p = 0.009). High activity BB phenotype did not occur in lupus. Lipid parameters and arylesterase activity were within normal range in both groups. No significant correlation was found between paraoxonase activity and disease activity index, dose of corticosteroid therapy, CRP and anti-oxLDL level. Arylesterase activity did not differ in lupus and control groups. Conclusions: Present results suggest that other mechanisms, e.g. antibodies, genetic factors, alteration in the distribution of HDL-subfractions or ensyme abnormalities in HDL remodelling may stand at the background of reduced paraoxonase activity in lupus.

KW - Atherosclerosis

KW - Inflammation

KW - Lipid profile

KW - Paraoxonase

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=33644854284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644854284&partnerID=8YFLogxK

M3 - Article

C2 - 16398152

AN - SCOPUS:33644854284

VL - 146

SP - 2395

EP - 2402

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -